AVBP — ARRIVENT BIOPHARMA, INC. COMMON STOCK (Healthcare >> Biotechnology)
AVBP FAQ
What is AVBP's ROE?
ARRIVENT BIOPHARMA, INC. COMMON STOCK reports a Return on Equity (ROE) of -44.83%.
What is AVBP's dividend yield?
ARRIVENT BIOPHARMA, INC. COMMON STOCK offers a dividend yield of 0.00%.
What is AVBP's Deepscope Quality Score?
Deepscope rates AVBP's overall financial quality at 38 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy AVBP?
Deepscope's AI Timing Score for AVBP is 91 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does AVBP belong to?
ARRIVENT BIOPHARMA, INC. COMMON STOCK is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 30.55
Price
0.05
(0.16%)
Day Change
|
|
|---|
AVBP Chất lượng tổng thể của cố phiếu Không tốt ( Chất lượng = 38) nhưng Thời điểm mua ...(Sign In to See)...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
Tỷ lệ ROE tương đối thấp
Tỷ lệ ROA tương đối thấp
Lịch sử ROE tương đối thấp
Tăng trưởng ROE là âm trong năm ngoái.
ROA quá thấp so với ROE
Tăng trưởng ROA dưới mức tiêu chí của chúng tôi trong năm vừa qua
Biên lợi nhuận ròng tương đối thấp.
Tốc độ tăng trưởng biên lợi nhuận ròng dưới mức tiêu chí của chúng tôi
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
Chi tiết hơn, sẽ thấy rằng các yếu tố chất lượng Không tốt , Sức khỏe tài chính Không tốt , và khả năng kiếm lợi nhuận Không tốt , ...
| Yếu tố Chất lượng |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 95 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 30.55 |
| PBV / Sector |
4.36 / 4.71
|
| Earning Per Share | -3.14 |
| PE / Sector |
N/A / 17.58
|
| PEG or PE/Growth / Sector |
N/A / 0.53
|
| Average 1M Daily Value |
15.98 M
GREAT
|
| Average 1W Daily Value |
17.73 M
GREAT
|
| Yếu tố Kỹ thuật |
|
71% |
| Sức khỏe tài chính |
|
41% |
| Khả năng kiếm lợi nhuận |
|
37% |
| Lợi tức cho nhà đầu tư |
|
8% |
| Chi tiết đăng ký |
| Analyze Date | 2026-06-10 09:43:46 |
| Symbol | AVBP |
| Name | ARRIVENT BIOPHARMA, INC. COMMON STOCK |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 46.57 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 1,413.55 / 8,889.42 |
| Tin tức, Dự báo ước tính |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 18 Campus Boulevard, Newtown Square, PA, United States, 19073
Phone: 628 277 4836
Website: https://arrivent.com
Employees: 77
Sector: Healthcare >> Biotechnology
Description: ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company's lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients. It is also developing ARR-217, an antibody drug conjugate (ADC) for the treatment of gastrointestinal cancers; and ARR-002, ARR-421, and ARR-173 for solid tumors. The company has strategic collaborations with Aarvik Therapeutics Inc., Shanghai Allist Pharmaceuticals Co., Ltd., Beijing InnoCare Pharma Tech Co., Ltd., Jiangsu Alphamab Biopharmaceuticals Co., Ltd., and Lepu Biopharma Co. Ltd. ArriVent BioPharma, Inc. was incorporated in 2021 and is based in Newtown Square, Pennsylvania.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
Google